脓毒症为重症医学科中常见病，也是消耗医疗资源最多的病种。血液净化为脓毒症的潜在治疗方向。但目前对血液净化治疗脓毒症的疗效仍有争论, 有关其适应证的选择及治疗的强度仍未达共识。我们在世界上首次建立了血液净化的大鼠模型，并对血液净化治疗脓毒症的机制进行了系统的阐述。我们最近几年对预测脓毒症发生，发展及预后的生物标志物进行了系统的筛查。标志物指导临床治疗已变得越来越重要，但这些指标对血液净化治疗脓毒症的指导意义尚未报道。本课题旨在用液相芯片分析系统，酶联免疫吸附技术，质谱仪等先进技术从脓毒症大鼠的血液、尿中分离筛选出生物标志物，寻找最佳的能预测监控脓毒症发展的标志物，选择最适浓度的标志物，并以此作为指导血液净化治疗的参照物,为进一步优化血液净化治疗脓毒症提供方向。

Sepsis is a common problem in critical care medicine, and also one of the main problems to induce the greatest expenditure of medical resources.Blood purification is potentially promising therapy for sepsis.However,the efficacy for blood purification used for sepsis is disputed, and the agreements for initial time and intensity of blood purification used for sepsis haven't been reached yet.We are the first in the world to set up the blood purification device in the rat models, and explore systemically the mechanisms of blood purification used in sepsis. We are also searching for the biomarkers to predict the development and outcome of sepsis. It becomes more and more important to guide therapies with these biomarkers, but they have never been used for blood purification.This project is to isolate the biomarkers from the blood and urine samples of septic rats using flow Luminex, ELISA, and mass-spectrometry. Then we validate and optimize the best biomarkers to predict the progress and outcome for sepsis. Finally we set up the cut-off values to initiate the starting time and intensity for blood purification, and compare the outcome between the biomarkers guided therapy and without-biomarkers guided therapy. This project will provide an ideal direction for blood purification used in sepsis.